Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.

Lancet Diabetes & Endocrinology is a premier peer-reviewed journal, published by Elsevier Science Inc, dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Established in 2013, this journal has quickly ascended to a position of notable prestige, reflected in its prestigious Q1 rank across various categories, including Endocrinology, Internal Medicine, and Diabetes & Metabolism. With an impressive impact factor and Scopus rankings placing it in the 99th percentile of its field, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal aims to disseminate high-quality research covering clinical and experimental aspects of metabolic and endocrine disorders, making it an indispensable tool for those looking to stay at the forefront of these rapidly evolving fields. With its focus on innovative depth and cutting-edge studies, Lancet Diabetes & Endocrinology continually fosters an international dialogue critical for advancements in diabetes and endocrinology.

The International Journal of Diabetes in Developing Countries, published by SPRINGER INDIA, stands as a pivotal resource in the field of diabetes research, particularly focusing on the challenges and advancements in diabetes management within developing nations. With an ISSN of 0973-3930 and an E-ISSN of 1998-3832, this journal has been fostering knowledge exchange since its inception in 2001, converging its focus over multiple years to maintain relevance through 2024. As a peer-reviewed journal, it holds a significant position within the Q4 category of Endocrinology, Diabetes and Metabolism and Q3 in Internal Medicine, showcasing its commitment to addressing critical issues regarding diabetes care in diverse populations. The journal is crucial for researchers, healthcare professionals, and students seeking to further their understanding of diabetes in resource-limited settings. Although it operates without an open access model, the journal ensures rigorous peer review, maintaining high academic standards that benefit the growing field of diabetes research. With its address located in the heart of New Delhi, India, this publication serves as a vital repository for valuable insights and innovative strategies aimed at combating diabetes in developing countries.

DIABETES & METABOLISM, published by MASSON EDITEUR in France, is a leading academic journal dedicated to the fields of endocrinology, diabetes, and metabolism. With an impressive Impact Factor reflecting its esteemed reputation, the journal has been ranked in the Q1 category across multiple disciplines including Endocrinology, Internal Medicine, and more, showcasing its significance and influence in the scientific community. Since its inception in 1996 and continuing its contributions through 2024, DIABETES & METABOLISM systematically disseminates high-quality research findings, reviews, and clinical studies aimed at furthering knowledge and encouraging innovation in metabolic diseases. Although not an open-access journal, it ensures that valuable research is accessible to a broad audience through institutional subscriptions and affiliations. As a key resource for researchers, clinicians, and students alike, this journal stands at the forefront of advancing understanding and treatment options in diabetes and related metabolic disorders, making it an essential addition to any academic library.

The British Journal of Diabetes, published by the Association of British Clinical Diabetologists, is a premier journal dedicated to advancing the understanding, prevention, and management of diabetes. With an ISSN of 2397-6233, this journal aims to disseminate high-quality research findings, clinical studies, and reviews that address the complexities of diabetes care and research. While currently not available as an open access option, the journal is committed to enhancing the visibility of cutting-edge diabetes research for healthcare professionals and academics. Located in the heart of England, this journal plays a crucial role in bridging the gap between clinical practice and research innovation, making it an essential resource for practitioners, researchers, and students alike. The British Journal of Diabetes is determined to contribute significantly to the global dialogue on diabetes, as it covers a wide spectrum of topics from epidemiology and public health to novel therapeutic strategies and patient management approaches.

Current Opinion in Endocrinology, Diabetes and Obesity, published by LIPPINCOTT WILLIAMS & WILKINS, offers a critical analysis of the latest advancements and trends in the fields of endocrinology, diabetes, and obesity. With an ISSN of 1752-296X and an E-ISSN of 1752-2978, this esteemed journal provides an authoritative platform for researchers, clinicians, and healthcare professionals to stay updated on emerging research and clinical practices. Renowned for its impactful contributions, the journal holds notable rankings, including Q2 in Endocrinology and Diabetes & Metabolism, as well as a commendable Q1 in Internal Medicine, reflecting its significance in the academic community. Although currently not an open access publication, articles published from 2007 to 2024 continually enrich the discourse on pressing health issues related to endocrinology and metabolic disorders. By fostering a comprehensive understanding of the complexities within these interconnected fields, it serves as an essential resource for any professional or student engaged in health science research.

DIABETIC MEDICINE is a leading peer-reviewed journal published by Wiley, dedicated to advancing the field of endocrinology, specifically focusing on the pathophysiology, management, and prevention of diabetes mellitus and its complications. With an impressive impact factor reflecting its significant role in shaping clinical practice and research, DIABETIC MEDICINE holds a prominent position among its peers, categorized in the Q1 quartiles for Endocrinology, Diabetes and Metabolism, and Internal Medicine. Since its inception in 1984, the journal has provided a platform for rigorous and innovative research, fostering collaborative efforts among researchers, clinicians, and students to enhance diabetes care. The journal is esteemed for its high-ranking performance in Scopus, highlighted by its ranking of #33 in Internal Medicine and #64 in Endocrinology, Diabetes, and Metabolism. By offering insightful access to groundbreaking studies and reviews, DIABETIC MEDICINE plays a crucial role in informing policy and improving medical outcomes for individuals with diabetes, making it an essential resource for those in medical and clinical research fields.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.

Diabetes Stoffwechsel und Herz, published by VERLAG KIRCHHEIM, is a distinguished journal that focuses on the interdisciplinary field of diabetes research, cardiology, and metabolic disorders. With its dedicated approach, the journal aims to disseminate cutting-edge findings and foster innovative discussions among researchers and practitioners in the healthcare community. Despite its discontinuation in Scopus coverage since 2017, the journal continues to hold significance in advancing knowledge regarding the intricate relationship between diabetes and cardiovascular health. It offers researchers a platform to explore the biochemical, genetic, and clinical aspects of endocrinology, while also catering to the needs of professionals aiming to apply the latest research in their practice. The journal’s rankings, which place it in the lower percentiles across various relevant categories, reflect a unique opportunity for contributors looking to impact a niche yet vital area of medicine. As the field evolves, Diabetes Stoffwechsel und Herz remains committed to enriching the dialogue surrounding these critical health issues.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.